NRC
NRC HEALTH
Next earnings Jul 27, 2026
Last earnings -1.6% on 2026-04-28
$20.81
▲ +1.31%$20.81▲ +26.63%
over 1Y
L $11.22EODHDH $22.27
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.3%
1W+6.8%
1M+8.8%
3M+21.5%
YTD+16.5%
1Y+26.6%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Sell
High return on equity (82.9%); but revenue declined -4.0% YoY.
Revenue (FY2025) $137M · FY2025
The read
It screens cheap (~1922% below fair value), but the weak fundamentals are why — more potential value trap than bargain.
NRC HEALTH shows $137M in FY2025 revenue (-4.0% YoY), a 8.4% net margin, and 82.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $148M | $152M | $149M | $143M | $137M |
| Gross profit | — | — | — | — | — |
| Operating income | $50.3M | $46.5M | $40.0M | $35.2M | $22.6M |
| Net income | $37.5M | $31.8M | $31.0M | $24.8M | $11.6M |
| Diluted EPS | $1.46 | $1.27 | $1.25 | $1.04 | $50.00 |
| Net margin | 25.3% | 21.0% | 20.8% | 17.3% | 8.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$545M
EV / EBITDA18.0
EV / Sales4.0
EV / FCF34.6
P / FCF30.1
PEG (trailing)—
Earnings yield2.5%
FCF yield3.3%
Quality & risk
ROIC (est.)19.8%
Free cash flow$15.7M
Total debt$76.1M
Net cash-$71.9M
Altman Z-Score3.60 safe
Piotroski F-Score5/8
Capital returns
Buyback yield4.3%
Dividend yield (est.)2.3%
Shareholder yield6.6%
Shares Δ YoY-0.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-28). Worth a closer look.
- DEF 14A Proxy statement2026-05-08
- 10-Q Quarterly report2026-05-06
- 8-K Officer / director change2026-04-28
- 8-K Earnings results2026-04-28
- 10-K/A Restated periodic report2026-04-28
- 8-K Officer / director change2026-04-20
- 8-K Reg FD disclosure2026-03-05
- 10-K Annual report2026-03-05
- 8-K Earnings results2026-02-03
Recent filings
all on EDGAR ↗4Period ending 2026-06-232026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗4Period ending 2026-06-232026-06-25open ↗SCHEDULE 13D/AFiling2026-06-12open ↗424B7Filing2026-05-13open ↗ARSPeriod ending 2025-12-312026-05-08open ↗DEFA14AFiling2026-05-08open ↗DEF 14APeriod ending 2026-06-232026-05-08open ↗10-QPeriod ending 2026-03-312026-05-06open ↗PRE 14APeriod ending 2026-06-232026-04-28open ↗
Frequently asked
- Is NRC HEALTH (NRC) a buy?
- NRC currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (82.9%); but revenue declined -4.0% YoY.
- What is NRC's fair value?
- A Modified-Graham model based on NRC's SEC fundamentals estimates a fair value of about $420.75. It is an estimate from reported earnings, not a price target.
- Is NRC overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, NRC currently appears undervalued relative to its SEC-grounded earnings power.
- What is NRC HEALTH's quality score?
- NRC scores 63.78431372549019/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000070487, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 8:13:36 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.